February 01, 2019

Cosentyx is a human interleukin-17A antagonist

According to pooled data from four Phase 3 studies, treatment with secukinumab (Cosentyx; Novartis) was associated with improvement in mobility, self-care, and usual activities (e.g., work, study, housework, family or leisure activities) when compared with placebo in patients with moderate-to-severe plaque psoriasis.

In the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, psoriasis patients who reported problems in these quality of life measures (through the EQ-5D-3L questionnaire) were randomized to receive secukinumab 300mg or placebo and were assessed at weeks 4, 8, and 12. Results showed that at week 4, the percentage of patients reporting no problems in mobility (60.7%), self-care (71.4%), or change in usual activities (63.8%) was higher in the secukinumab group than in the placebo arm (38.5%, 40.9%, and 31.1%, respectively); similar trends were observed at week 8 and 12.

“Moderate-to-severe plaque psoriasis can impact every aspect of a person’s life,” stated Steven R. Feldman, MD, PhD, Wake Forest School of Medicine. “These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management.”

Cosentyx, a human interleukin-17A antagonist, is FDA-approved for the treatment of: moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy; adults with active psoriatic arthritis; and adults with active ankylosing spondylitis.

Follow @DermAdvisor

For more information visit Novartis.com.